ATROGIN-1抗体 新品

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Flow cytometric analysis of Hela cells using ATROGIN-1 Rat mAb (green) and negative control (red).    

  
  

The ATROGIN-1 antibody is a crucial tool for studying muscle atrophy and protein degradation pathways. ATROGIN-1. also known as MAFbx (Muscle Atrophy F-box), is an E3 ubiquitin ligase encoded by the *FBXO32* gene. It plays a central role in the ubiquitin-proteasome system (UPS), tagging specific substrates for degradation. Discovered in 2001. ATROGIN-1 gained attention due to its rapid upregulation during skeletal muscle atrophy triggered by conditions like fasting, denervation, disuse, or cancer cachexia. It works in tandem with MuRF1 (another E3 ligase), targeting key structural and regulatory proteins such as MyoD and eIF3-f for proteasomal breakdown, thereby promoting muscle loss.

Antibodies against ATROGIN-1 are widely used in research to detect protein expression levels in tissues or cell cultures, employing techniques like Western blotting, immunohistochemistry, and immunofluorescence. These reagents help elucidate mechanisms underlying muscle wasting in diseases (e.g., muscular dystrophy, cancer, sepsis) or age-related sarcopenia. Validation of ATROGIN-1 antibodies often involves testing in knockout models or atrophy-inducing conditions to confirm specificity. Beyond basic research, such antibodies hold potential for developing diagnostic biomarkers or therapeutic strategies to modulate UPS activity. However, variability in antibody performance across species or experimental setups requires careful optimization. Overall, ATROGIN-1 antibodies remain indispensable for exploring cellular proteostasis and muscle biology.